

February 14, 2013

From	То
Pasi Korhonen, Principal Investigator	Paul Dolin
EPID Research	Director, Epidemiology
Tekniikantie 12, FI-02150 Espoo, FINLAND	Takeda Global Research & Development Centre (Europe) Ltd
tel. +358-50-365-2990	61 Aldwych, London, WC2B 4AE, United Kingdom
email: pasi.korhonen@epidresearch.com	

Reference:

"Pan European Multi-Database Bladder Cancer Risk Characterisation Study": the ENCePP Seal

To whom it may concern,

The Medicinal Products of Human Use (CHMP) of the European Medicines Agency (EMA) has requested Takeda Global Research & Development Centre Europe Ltd (Takeda) to conduct a post-authorisation safety study (PASS) on pioglitazone use and occurrence of bladder cancer.

The study protocol, includes a statement that the study will be submitted for ENCePP Seal of Approval. The ENCePP Seal requires making the study data from each dataset as well as the pooled dataset available to 3rd parties. The investigators (including research partners EPID Research, PHARMO, CPRD and Karolinska Institutet) of the study fully support the transparency principle of observational research, but are not able to commit to making the data available to 3rd parties at this time. Local governance of the use of the datasets for medical research purposes does not permit the investigators to provide the data to 3rd parties. As members of the ENCePP I myself and another study investigator (Helle Kieler) are bringing this issue back to ENCePP for further consideration and discussion on how investigators can meet the criteria of sharing data to 3rd parties.

For the reasons mentioned the investigators agreed not to apply for the ENCePP Seal but only to register the study in ENCePP E-Register of Studies.

For the Study group,

Pasi Korhonen (PhD, Adj. prof. biostatistics)

Principal investigator

Co-Investigators	
Ron M.C. Herings, PhD	Rachael Boggon, PhD
Scientific Director	Research Statistician
Pharmo Institute for Drug Outcomes Research	The Clinical Practice Research Datalink Group (CPRD)
(PHARMO)	The Medicines and Healthcare products Regulatory Agency
Van Deventerlaan 30-40	151 Buckingham Palace Road
3528 AE Utrecht	London SW1W 9SZ
The Netherlands	England
Helle Kieler, MD, PhD	
Associate Professor	
Head, Centre for Pharmacoepidemiology	
Karolinska Institutet T2,	
Karolinska University Hospital	
SE 171 76 Stockholm Sweden	